ITEMS IN AFP WITH KEYWORD:
Long-acting muscarinic antagonists added to inhaled corticosteroids are a superior treatment to placebo for improving asthma control in adults and children 12 years or older. Long-acting muscarinic antagonist add-on therapy is not superior to long-acting beta agonist (LABA) add-on therapy.
When compared with standard therapy (inhaled corticosteroids with or without LABAs and SABAs as relief therapy), SMART is associated with a reduced risk of acute asthma exacerbations in patients 12 years or older.
Jun 1, 2018 Issue
Combined Inhaled Short-Acting Beta2 Agonist and Anticholinergic Agents for Asthma [Medicine by the Numbers]
Although the quality of evidence included in this review was low to moderate, the potential benefits of decreased hospitalization and relapse rates and the comparatively mild and limited adverse events suggest that patients presenting with acute asthma exacerbations are likely to benefit from combin...
Learn the results of a Cochrane review which studied the effectiveness of Qvar in two sets of patients with chronic asthma: those receiving oral corticosteroids and those not receiving them.
Mar 1, 2018 Issue
Combination LABA Inhalers Compared with High-Dose Inhaled Steroids for Adults with Asthma [Medicine by the Numbers]
We designated the use of long-acting beta agonist inhalers for adults with asthma as having no benefits because of a small potential benefit of questionable clinical utility (avoiding a brief burst of oral steroids) and the possibility of a fatal harm. Find out more.
In children with house dust mite allergies and asthma, the use of mite-impermeable bedding decreases the frequency of asthma exacerbations.
Reslizumab is an expensive treatment option for decreasing exacerbations in patients with severe asthma and pronounced eosinophilia. Because of the risk of anaphylaxis, it should only be administered in an appropriate facility by a medical professional. Reslizumab is best considered after other treatments have proved ineffective.
Despite the authors' caution that further data are needed to clarify the role of vitamin D in care, this Cochrane review found that its use reduces the average number of asthma exacerbations requiring corticosteroid treatment from 0.44 to 0.28 per person per year.
Regular yoga improves quality of life as measured on the Asthma Quality of Life Questionnaire (mean difference = 0.57 units on a seven-point scale; 95% confidence interval [CI], 0.37 to 0.77); improves asthma symptoms (standardized mean difference = 0.37; 95% CI, 0.09 to 0.65); and reduces medicatio...
This study found that current asthma was ruled out after repeated testing in one-third of adults with physician-diagnosed asthma. Patients ruled out for current asthma were less likely to be using asthma medications or daily controlling medications and less likely to have undergone testing for airflow limitation at the time of initial diagnosis.